gdc

April 2021 Vol 7 No 2

No Pair, I Don’t Care!
Breast CancerCOVID-19 & CancerPatient Stories
In May 2019, Kiana Wooten went for a routine check-up. Read about how that routine visit turned into a breast cancer diagnosis for the 34-year-old Kiana, who had to be hospitalized during COVID-19.
Exposure to Occupational Toxins Increases the Risk for Lung Cancer
Lung Cancer
Learning about lung cancer risks is important. An issue that needs more awareness is occupational exposure to harmful chemicals and the negative effects such exposure has on our health.
Libtayo Approved for First-Line Treatment of Advanced Lung Cancer
FDA Approvals, News & UpdatesLung Cancer
The immunotherapy Libtayo received FDA approval as first-line treatment for patients with advanced or metastatic non–small-cell lung cancer and high PD-L1 expression.
Libtayo Approved for Some Patients with Basal-Cell Carcinoma
FDA Approvals, News & UpdatesSkin Cancer
The immunotherapy Libtayo is a new treatment option for advanced or metastatic basal-cell carcinoma, a type of skin cancer. Libtayo was initially approved for a different type of skin cancer.
Deadly Kicks from the “C” Word
COVID-19 & CancerPatient Stories
Sabrina Steinback’s mom died from COVID-19 in 2020, and then Sabrina had a lumpectomy to remove breast cancer at the end of the year.
FDA Approved Pepaxto for Relapsed or Refractory Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
Pepaxto is a novel therapy that has shown good results in multiple myeloma that does not respond to other therapies, according to myeloma expert Paul G. Richardson, MD, of Dana-Farber Cancer Institute.
FDA Approves Abecma, First CAR T-Cell Therapy for Multiple Myeloma
FDA Approvals, News & UpdatesMultiple Myeloma
Abecma is the first gene therapy approved by the FDA for patients with multiple myeloma. It uses the patient’s own genetically modified T-cells to fight the cancer.
Yescarta First Gene Therapy Approved for Follicular Lymphoma
FDA Approvals, News & UpdatesFollicular Lymphoma
Yescarta is the first CAR T-cell therapy approved by the FDA for patients with follicular lymphoma. It uses the patient’s own genetically modified T-cells to fight the cancer.
FDA Approved Ukoniq, New Targeted Therapy, for Marginal-Zone and Follicular Lymphoma
FDA Approvals, News & UpdatesLymphomaFollicular Lymphoma
Ukoniq is the first dual inhibitor of PI3K-delta and CK1-epsilon to be approved by the FDA, and is the first targeted, once-daily oral therapy option for marginal-zone or follicular lymphoma.
FDA Approved Breyanzi, Novel Gene Therapy, for Large B-Cell Lymphoma
FDA Approvals, News & UpdatesLymphoma
“Today’s approval represents another milestone in the rapidly progressing field of gene therapy,” said Peter Marks, MD, PhD, Director of the FDA’s Center for Biologics Evaluation and Research.
Page 1 of 3
Results 1 - 10 of 23

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country
Gender
Race or Ethnicity
Profession or Role
Primary Interest